Biomaterial Database

Release profiles of phenytoin from new oral dosage form for the elderly. 1994

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

Pharmaceutical Department, Tokyo Women's Medical College, Japan.

Utilization of the solid mass containing phenytoin, sodium caseinate and microcrystalline cellulose (MCC) as a new dosage form for the elderly was studied. The solid mass was prepared by treatment of the powder mixture with high pressure steam at 115 degrees C for 10 min. The stability of phenytoin in the solid mass was confirmed by infrared spectroscopy and high performance liquid chromatography. The extent of swelling of the solid mass containing phenytoin was investigated by water absorption test and gel strength test, and the swelling property was almost independent of the presence of phenytoin. The release profile of phenytoin from the solid mass was determined under various conditions, and was found to be influenced by the extent of swelling and the swollen state. It was observed that the protein adsorption to the phenytoin crystal surface and the addition of digestive enzyme also affected the release profile. In water, the solid mass prepared from a ground mixture of phenytoin and MCC showed remarkable improvement of release profile of phenytoin.

UI	MeSH Term	Description	Entries
D010672	Phenytoin	An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.	Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002364	Caseins	A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.	alpha-Casein,gamma-Casein,AD beta-Casein,Acetylated, Dephosphorylated beta-Casein,Casein,Casein A,K-Casein,Sodium Caseinate,alpha(S1)-Casein,alpha(S1)-Casein A,alpha(S1)-Casein B,alpha(S1)-Casein C,alpha(S2)-Casein,alpha-Caseins,beta-Casein,beta-Caseins,epsilon-Casein,gamma-Caseins,kappa-Casein,kappa-Caseins,AD beta Casein,Caseinate, Sodium,K Casein,alpha Casein,alpha Caseins,beta Casein,beta Caseins,beta-Casein Acetylated, Dephosphorylated,beta-Casein, AD,epsilon Casein,gamma Casein,gamma Caseins,kappa Casein,kappa Caseins
D004304	Dosage Forms	Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect.	Dosage Form,Form, Dosage,Forms, Dosage
D004355	Drug Stability	The chemical and physical integrity of a pharmaceutical product.	Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042	Absorption	The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000284	Administration, Oral	The giving of drugs, chemicals, or other substances by mouth.	Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D016503	Drug Delivery Systems	Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.	Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug

Related Publications

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

A new oral gelatinized sustained-release dosage form.

July 1963, Journal of pharmaceutical sciences,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

Computer-aided dosage form design. III. Feasibility assessment for an oral prolonged-release phenytoin product.

February 1991, Pharmaceutical research,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

Phenytoin dosage in the elderly.

August 1977, Age and ageing,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

New oral solid dosage form for furosemide oral administration.

April 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol.

March 2004, British journal of clinical pharmacology,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

[A new dosage form of indomethacin. Pharmaceutical profile of an oral form with osmotically controlled release].

January 1983, Annales pharmaceutiques francaises,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

[Design and application of oral sustained-release anticancer drug--a new oral dosage form of cisplatin].

March 1998, Nihon rinsho. Japanese journal of clinical medicine,

A Watanabe, and T Hanawa, and M Sugihara, and K Yamamoto

Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form.

February 2020, Drug delivery and translational research,